MRKR

1.09017.42%
HE

Helen E. Heslop

Member of Scientific Advisory Board

Dr. Helen E. Heslop, M.D., D.Sc., is a co-founder of ViraCyte, LLC. Dr. Heslop has been a Member of Medical & Scientific Advisory Board at Cyto-Sen Therapeutics, Inc. since October 23, 2017 and Marker Therapeutics, Inc. (formerly known as TapImmune, Inc.) since 2018. Dr. Heslop is a Professor of Medicine and Pediatrics at Baylor College of Medicine and the Director of the Center for Cell and Gene Therapy at Baylor College of Medicine, Houston Methodist Hospital and Texas Children's Hospital. She is also Associate Director for Clinical Research at the Dan L Duncan Cancer Center. Dr. Heslop is a physician scientist engaged in translational research focusing on adoptive immunotherapy with gene-modified effector cells, to improve hemopoietic stem cell transplantation and cancer therapy. She has extensive experience in developing and conducting transplant studies and cell and gene therapy studies. Dr. Heslop was a Doris Duke Distinguished Clinical Research Scientist and serves as the current President elect of the American Society for Gene and Cell Therapy (ASGCT) and a past President of the Foundation for Accreditation of Cell Therapy (FACT) and the American Society of Blood and Marrow Transplantation. She received her M.B.ChB, M.D. and D.Sc. (Hon) in Hematology from the University of Otago in New Zealand.

Positions